XDx Forms Deal with LabCorp

Xconomy San Francisco — 

XDx, the Brisbane, CA-based maker of molecular diagnostics, said today it has entered into a multi-year agreement with Laboratory Corporation of America (NYSE: LH). Under the deal, heart transplant patients eligible for XDx’s AlloMap test can get their blood drawn for testing at participating LabCorp sites around the U.S., and LabCorp will be the preferred third-party, non-hospital provider of specimen processing in North America. Terms of the deal weren’t disclosed. CEO Pierre Cassigneul told Xconomy last year that he thinks XDx will be able to turn its first profit in 2011.